Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study

Fineline Cube Feb 20, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...

Company Drug

Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia

Fineline Cube Feb 20, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that its biosimilar of Roche’s Avastin (bevacizumab), Hanbeitai,...

Company Drug

Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML

Fineline Cube Feb 20, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503, OTCMKTS: ALPMY ) announced that the National Medical Products...

Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study

Fineline Cube Feb 20, 2025

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...

Company Medical Device

Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement

Fineline Cube Feb 20, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received marketing approval from...

Company Deals

Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development

Fineline Cube Feb 20, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...

Company

Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment

Fineline Cube Feb 20, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...

Company Deals

Jiangxi Rimag Group and Xunfei Healthcare Form Strategic Alliance for Smart Healthcare

Fineline Cube Feb 20, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced a strategic alliance with Xunfei Healthcare...

Company Deals

Rendu Biotechnology Partners with Green Apple Medical System for RNA Diagnostics Expansion

Fineline Cube Feb 20, 2025

Rendu Biotechnology Co., Ltd., (SHA: 688193) a Shanghai-based specialist in RNA molecular diagnostics, has entered...

Company Deals

Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline

Fineline Cube Feb 20, 2025

China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...

Company Legal / IP

AstraZeneca Faces Class Action Lawsuits Over China Legal Issues

Fineline Cube Feb 20, 2025

AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...

Company Deals Drug

Biogen Licenses Stoke Therapeutics’ Zorevunersen for Dravet Syndrome Outside Americas

Fineline Cube Feb 19, 2025

US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc....

Company Drug

TAHO Pharma’s TAH3311 Oral Film Shows Bioequivalence to Eliquis in Study

Fineline Cube Feb 19, 2025

Taiwan-based TAHO Pharmaceuticals announced positive preliminary results from a pivotal study for its TAH3311 oral...

Company Drug

Sanofi’s Dupixent Receives Priority Review from FDA for Bullous Pemphigoid Treatment

Fineline Cube Feb 19, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that the US Food and Drug Administration (FDA) has...

Company Deals

CSPC Pharma Licenses SYS 6005 to Radiance Biopharma for Global Markets

Fineline Cube Feb 19, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a licensing agreement with Radiance Biopharma, Inc.,...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Receives NMPA Approval for Phase II/III Study in HER2+ Breast Cancer

Fineline Cube Feb 19, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review

Fineline Cube Feb 19, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that the New Drug Application (NDA) for its...

Company Drug

Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC

Fineline Cube Feb 19, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that it has received...

Company

GSK and Abbott Announce Leadership Changes in Key Roles

Fineline Cube Feb 19, 2025

Recent days have seen significant leadership changes at two pharmaceutical giants: UK-based GSK plc (LON:...

Company

Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation

Fineline Cube Feb 19, 2025

US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3)...

Posts pagination

1 … 262 263 264 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.